Caseware UK (AP4) 2023.0.135 2023.0.135 2024-02-292024-02-2922023-03-01falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.medical consultancy2falsetrue 13226756 2023-03-01 2024-02-29 13226756 2022-03-01 2023-02-28 13226756 2024-02-29 13226756 2023-02-28 13226756 c:Director1 2023-03-01 2024-02-29 13226756 d:FurnitureFittings 2023-03-01 2024-02-29 13226756 d:FurnitureFittings 2024-02-29 13226756 d:FurnitureFittings 2023-02-28 13226756 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-03-01 2024-02-29 13226756 d:CurrentFinancialInstruments 2024-02-29 13226756 d:CurrentFinancialInstruments 2023-02-28 13226756 d:CurrentFinancialInstruments d:WithinOneYear 2024-02-29 13226756 d:CurrentFinancialInstruments d:WithinOneYear 2023-02-28 13226756 d:ShareCapital 2024-02-29 13226756 d:ShareCapital 2023-02-28 13226756 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2024-02-29 13226756 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2023-02-28 13226756 c:FRS102 2023-03-01 2024-02-29 13226756 c:AuditExempt-NoAccountantsReport 2023-03-01 2024-02-29 13226756 c:FullAccounts 2023-03-01 2024-02-29 13226756 c:PrivateLimitedCompanyLtd 2023-03-01 2024-02-29 iso4217:GBP xbrli:pure

Registered number: 13226756









ACS ENDOSCOPY LIMITED







UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 29 FEBRUARY 2024

 
ACS ENDOSCOPY LIMITED
REGISTERED NUMBER: 13226756

BALANCE SHEET
AS AT 29 FEBRUARY 2024

29 February
28 February
2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
1,367
768

  
1,367
768

Current assets
  

Cash at bank and in hand
 5 
41,484
32,069

  
41,484
32,069

Creditors: amounts falling due within one year
 6 
(42,751)
(32,737)

Net current liabilities
  
 
 
(1,267)
 
 
(668)

Total assets less current liabilities
  
100
100

  

Net assets
  
100
100


Capital and reserves
  

Called up share capital 
  
100
100

  
100
100

Page 1

 
ACS ENDOSCOPY LIMITED
REGISTERED NUMBER: 13226756
    
BALANCE SHEET (CONTINUED)
AS AT 29 FEBRUARY 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 20 September 2024.




................................................
Angel Castro Silva
Director

The notes on pages 3 to 6 form part of these financial statements.
Page 2

 
ACS ENDOSCOPY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

1.


General information

ACS Endoscopy Limited is a private company, incorporated in England and Wales, limited by its share capital.  The principle activity of the Company was the provision of medical services.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

 
2.4

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 3

 
ACS ENDOSCOPY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

2.Accounting policies (continued)


2.4
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Fixtures and fittings
-
20%
reducing balance

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.7

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

 
2.8

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2023 - 2).

Page 4

 
ACS ENDOSCOPY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

4.


Tangible fixed assets







Fixtures and fittings

£



Cost or valuation


At 1 March 2023
1,200


Additions
941



At 29 February 2024

2,141



Depreciation


At 1 March 2023
432


Charge for the year on owned assets
342



At 29 February 2024

774



Net book value



At 29 February 2024
1,367



At 28 February 2023
768


5.


Cash and cash equivalents

29 February
28 February
2024
2023
£
£

Cash at bank and in hand
41,484
32,069

41,484
32,069


Page 5

 
ACS ENDOSCOPY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

6.


Creditors: Amounts falling due within one year

29 February
28 February
2024
2023
£
£

Corporation tax
5,761
4,499

Other creditors
35,730
27,038

Accruals and deferred income
1,260
1,200

42,751
32,737



7.


Financial instruments

29 February
28 February
2024
2023
£
£

Financial assets


Financial assets measured at fair value through profit or loss
41,484
32,069




Financial assets measured at fair value through profit or loss comprise cash at bank and in hand.


8.


Controlling party

The Company is controlled by Angel Castro Silva, by virtue of his shareholding, as described in the Directors' report.

 
Page 6